ReviewCurrent cardiology reports2020
Management of Patients with Acute Coronary Syndrome and Cancer.
Review in Current cardiology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Quality of care and long-term survival after ST-elevation myocardial infarction in adults with cancer.European heart journal. Quality of care & clinical outcomes · 2025Article
- Postmarketing safety evaluation of pemetrexed using FAERS and JADER databases.Scientific reports · 2025Article
- Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer.JACC. CardioOncology · 2024Article
- Comparisons of drug-eluting balloon versus drug-eluting stent for the treatment of cancer patients presenting with acute myocardial infarction.European journal of medical research · 2023Article
- EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.HemaSphere · 2022Article
- Management of Acute Coronary Syndrome in Cancer Patients: It's High Time We Dealt with It.Journal of clinical medicine · 2022Review
- Cancer-Associated Atherothrombosis: The Challenge.The International journal of angiology : official publication of the International College of Angiology, Inc · 2021Review
- Repurposing approved drugs for cancer therapy.British medical bulletin · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer patients with acute coronary syndrome (ACS) have significantly greater mortality compared with non-cancer patients. This risk is partly directly attributable to the malignancy; however these patients are frequently undertreated with respect to guideline recommended treatments for ACS due to higher bleeding risks from anemia and thrombocytopenia. Due to exclusion from large clinical trials, there is a paucity of data regarding how to best treat these complex and high-risk patients. PURPOSE OF REVIEW: To review the literature and identify risk factors among cancer patients associated with poor outcomes, pathophysiology of chemotherapy and radiation therapy contributing to accelerated coronary artery disease and ACS, and data regarding outcomes with medical therapy and invasive management. RECENT
findingsDespite an elevated bleeding risk, many cancer patients may benefit from ACC/AHA guideline-directed management for ACS including aspirin, P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.